Dechert advised Royalty Pharma on the deal.Royalty Pharma plc executed its acquisition of a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK)…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
